source
- Dutch court blocks Merck's subcutaneous Keytruda sales in eight European countries after Halozyme patent winA Netherlands court issued an injunction that stops Merck from marketing its subcutaneous formulation of Keytruda, known as Keytruda Qlex, in eight European markets. The ruling follows a patent in…
- BMO sees Merck better positioned than BMS to handle looming patent cliffsBMO Capital Markets says Merck has a stronger plan than Bristol Myers Squibb to replace revenue lost to upcoming patent expirations. The firm highlights Merck's pipeline as more derisked and sizabl…